Filing Flows › Amneal Pharmaceuticals (AMRX) › R&D spending
Amneal Pharmaceuticals (AMRX) R&D spending by quarter
Amneal Pharmaceuticals' R&D spending was $68.4M in Q3 2026 (third quarter 2026), +75% from Q2 2026. Over the last 6 quarters it ranged from $34.8M (Q4 2025) to $68.4M (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $68.4M | +75% | +8% |
| Q2 2026 | $39.0M | +2% | -19% |
| Q1 2026 | $38.4M | +10% | — |
| Q4 2025 | $34.8M | -45% | — |
| Q3 2025 | $63.4M | +32% | — |
| Q2 2025 | $48.0M | — | — |
Q3 2026 at a glance
Amneal Pharmaceuticals, Q3 2026: revenue $863M (+10% year over year), operating margin 11.1%, net earnings $12.3M, operating cash flow $98.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is Amneal Pharmaceuticals' R&D spending?
Amneal Pharmaceuticals' R&D spending was $68.4M in Q3 2026 (third quarter 2026), +75% from Q2 2026.
How has Amneal Pharmaceuticals' R&D spending changed?
Over the last 6 quarters it ranged from $34.8M (Q4 2025) to $68.4M (Q3 2026).
Q3 2026 results → · How Amneal Pharmaceuticals makes money →